Summary
83 / 100 · Bulios Score
What speaks for it
- Out of every 100 DKK of revenue, 20 DKK is left as net profit.
- It holds more cash than debt: 1.73B kr against 420.5M kr.
- It earns 16 DKK a year on every 100 DKK of invested capital.
- Revenue grew by 12% a year over the last 3 years.
What to watch
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 36.2 DKK for 1 DKK of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (DKK)
Diluted EPS (DKK)
- Analyst estimate
Revenue grew by 13% a year over 5 years. Over the last 3 years it grew by 12% a year. For the next fiscal year analysts expect revenue to grow by 16%.
Growth in detailDoes it make money?
Very wellWhere 100 DKK of revenue goes
- Cost of sales 32 DKK
- Research and development 9.6 DKK
- Sales and administration 32 DKK
- Taxes and other 6.9 DKK
- Net profit 20 DKK
Net profit, industry median (Biotechnology) -7.3 DKK
Out of every 100 DKK of revenue, 20 DKK is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 0.68%
- Paid out of profit
- 25%
You receive $0.25 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 1
- Hold 0
- Sell 0
No analyst has published a price target.
100% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.